Literature DB >> 22623042

Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis.

Hideyuki Nemoto1, Keiko Kataoka, Hideki Ishikawa, Kazue Ikata, Hideki Arimochi, Teruaki Iwasaki, Yoshinari Ohnishi, Tomomi Kuwahara, Koji Yasutomo.   

Abstract

BACKGROUND: Clinical observations and experimental colitis models have indicated the importance of intestinal bacteria in the etiology of ulcerative colitis (UC), but a causative bacterial agent has not been identified. AIM: To determine how intestinal bacteria are associated with UC, fecal microbiota and other components were compared for UC patients and healthy adults.
METHODS: Fresh feces were collected from 48 UC patients. Fecal microbiota were analyzed by use of terminal-restriction fragment length polymorphism (T-RFLP), real-time PCR, and culture. The concentrations of organic acids, indole, and ammonia, and pH and moisture, which are indicators of the intestinal environment, were measured and compared with healthy control data.
RESULTS: T-RFLP data divided the UC patients into four clusters; one cluster was obtained for healthy subjects. The diversity of fecal microbiota was significantly lower in UC patients. There were significantly fewer Bacteroides and Clostridium subcluster XIVab, and the amount of Enterococcus was higher in UC patients than in healthy subjects. The fecal concentration of organic acids was significantly lower in UC patients who were in remission.
CONCLUSION: UC patients have imbalances in the intestinal environment-less diversity of fecal microbiota, lower levels of major anaerobic bacteria (Bacteroides and Clostridium subcluster XIVab), and a lower concentration of organic acids.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623042     DOI: 10.1007/s10620-012-2236-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  57 in total

1.  Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces.

Authors:  Takahiro Matsuki; Koichi Watanabe; Junji Fujimoto; Yukiko Miyamoto; Toshihiko Takada; Kazumasa Matsumoto; Hiroshi Oyaizu; Ryuichiro Tanaka
Journal:  Appl Environ Microbiol       Date:  2002-11       Impact factor: 4.792

2.  In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.

Authors:  Sydney M Finegold; Shahera St John; Ann W Vu; Calida M Li; Denise Molitoris; Yuli Song; Chengxu Liu; Hannah M Wexler
Journal:  Anaerobe       Date:  2004-08       Impact factor: 3.331

3.  Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial.

Authors:  E Furrie; S Macfarlane; A Kennedy; J H Cummings; S V Walsh; D A O'neil; G T Macfarlane
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

4.  Towards the human intestinal microbiota phylogenetic core.

Authors:  Julien Tap; Stanislas Mondot; Florence Levenez; Eric Pelletier; Christophe Caron; Jean-Pierre Furet; Edgardo Ugarte; Rafael Muñoz-Tamayo; Denis L E Paslier; Renaud Nalin; Joel Dore; Marion Leclerc
Journal:  Environ Microbiol       Date:  2009-07-06       Impact factor: 5.491

5.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

6.  Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis.

Authors:  Akira Andoh; Shinji Sakata; Yuhsuke Koizumi; Keiichi Mitsuyama; Yoshihide Fujiyama; Yoshimi Benno
Journal:  Inflamm Bowel Dis       Date:  2007-08       Impact factor: 5.325

7.  Identification and quantitation of mucosal and faecal desulfovibrios using real time polymerase chain reaction.

Authors:  A Fite; G T Macfarlane; J H Cummings; M J Hopkins; S C Kong; E Furrie; S Macfarlane
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

8.  Treatment of ulcerative colitis using fecal bacteriotherapy.

Authors:  Thomas J Borody; Eloise F Warren; Sharyn Leis; Rosa Surace; Ori Ashman
Journal:  J Clin Gastroenterol       Date:  2003-07       Impact factor: 3.062

9.  Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease.

Authors:  Tanja Kuehbacher; Ateequr Rehman; Patricia Lepage; Stephan Hellmig; Ulrich R Fölsch; Stefan Schreiber; Stephan J Ott
Journal:  J Med Microbiol       Date:  2008-12       Impact factor: 2.472

10.  Enterococcus faecalis strains differentially regulate Alix/AIP1 protein expression and ERK 1/2 activation in intestinal epithelial cells in the context of chronic experimental colitis.

Authors:  Micha Hoffmann; Sandra C Kim; R Balfour Sartor; Dirk Haller
Journal:  J Proteome Res       Date:  2009-03       Impact factor: 4.466

View more
  52 in total

Review 1.  Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease.

Authors:  Janka Babickova; Roman Gardlik
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

Review 2.  Enteric microbiota leads to new therapeutic strategies for ulcerative colitis.

Authors:  Wei-Xu Chen; Li-Hua Ren; Rui-Hua Shi
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

3.  Molecular details of a starch utilization pathway in the human gut symbiont Eubacterium rectale.

Authors:  Darrell W Cockburn; Nicole I Orlovsky; Matthew H Foley; Kurt J Kwiatkowski; Constance M Bahr; Mallory Maynard; Borries Demeler; Nicole M Koropatkin
Journal:  Mol Microbiol       Date:  2014-12-19       Impact factor: 3.501

Review 4.  Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease.

Authors:  Zi-Kai Wang; Yun-Sheng Yang; Ye Chen; Jing Yuan; Gang Sun; Li-Hua Peng
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

5.  Dose-response relationship between cigarette smoking and risk of ulcerative colitis: a nationwide population-based study.

Authors:  Seona Park; Jaeyoung Chun; Kyung-Do Han; Hosim Soh; Eun Ae Kang; Hyun Jung Lee; Jong Pil Im; Joo Sung Kim
Journal:  J Gastroenterol       Date:  2019-05-15       Impact factor: 7.527

6.  Rising Rates of Severe Obesity in Adults Younger Than 50 Correspond to Rise in Hospitalizations for Non-malignant Gastrointestinal Disease.

Authors:  Arsheya Patel; Somashekar G Krishna; Kishan Patel; Darrell M Gray; Khalid Mumtaz; Peter P Stanich; Alice Hinton; Hisham Hussan
Journal:  Dig Dis Sci       Date:  2022-06-15       Impact factor: 3.199

Review 7.  Mucosal healing and deep remission: what does it mean?

Authors:  Gerhard Rogler; Stephan Vavricka; Alain Schoepfer; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Combination of metagenomics and culture-based methods to study the interaction between ochratoxin a and gut microbiota.

Authors:  Mingzhang Guo; Kunlun Huang; Siyuan Chen; Xiaozhe Qi; Xiaoyun He; Wen-Hsing Cheng; Yunbo Luo; Kai Xia; Wentao Xu
Journal:  Toxicol Sci       Date:  2014-06-27       Impact factor: 4.849

9.  Effect of fermented vegetable beverage containing Pediococcus pentosaceus in patients with mild to moderate ulcerative colitis.

Authors:  Shigeki Bamba; Kenichiro Takahashi; Hirotsugu Imaeda; Atsushi Nishida; Masahiro Kawahara; Osamu Inatomi; Mitsushige Sugimoto; Masaya Sasaki; Akira Andoh
Journal:  Biomed Rep       Date:  2018-05-18

Review 10.  Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier.

Authors:  Shui-Jiao Chen; Xiao-Wei Liu; Jian-Ping Liu; Xi-Yan Yang; Fang-Gen Lu
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.